AR and prostate carcinoma: For instance, it was observed that the in vitro, long-term treatment of prostate cancer cells with enzalutamide up to 5 μmol/L induced drug resistance and prolonged AR signaling suppression, as well as the downregulation of the cell cycle, Wnt signaling, and DNA repair pathways [33].